Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 5/20 | 0.35 |
| ▸ | ARG2 | P78540 | 4/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911367 | 0.77 | DGAT1 (0.32) | MEN1KMT2AGAA | |
| SCHEMBL4909430 | 0.76 | DGAT1 (0.32) | MEN1KMT2AGAA | |
| SCHEMBL2550935 | 0.74 | CTSK (0.36) | ARG1ARG2CYP1A2MEN1KMT2A | |
| SCHEMBL6429318 | 0.73 | ARG1 (0.42) | ARG1ARG2CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL4743247 | 0.72 | L3MBTL1 (0.40) | ARG1ARG2L3MBTL1CYP1A2MAPK1 | |
| SCHEMBL9116850 | 0.71 | DGAT1 (0.40) | ARG1ARG2CYP1A2MEN1KMT2A | |
| SCHEMBL4939145 | 0.71 | DGAT1 (0.40) | ARG1ARG2CYP1A2MEN1KMT2A | |
| SCHEMBL28195825 | 0.71 | DGAT1 (0.40) | ARG1ARG2CYP1A2MEN1KMT2A | |
| SCHEMBL21409064 | 0.70 | CTSK (0.44) | MAPK1 | |
| SCHEMBL21409067 | 0.70 | CTSK (0.44) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | DOMPE PHA.R.MA S.P.A. (IT) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | C5AR2, C3AR1, C5AR1 | ARG1 603/4885ARG2 318/4885NPSR1 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.